October 29, 2015:
Nymox Pharmaceutical Corporation reported today that long-term randomized cross-over data from the Companys trial of fexapotide triflutate for low grade localized prostate cancer has shown statistical significance in efficacy compared to controls.
August 4, 2015:
Nymox Pharmaceutical Corporation is pleased to announce that the Company has received formal approvals for its change of domicile to the Bahamas effective July 31, 2015.
July 30, 2015:
Nymox Pharmaceutical Corporation is pleased to announce that the Company has newly appointed James G. Robinson to the Board of Directors.
July 28, 2015:
(July 28, 2015) Nymox’s (NASDAQ:NYMX) July 27th webcast of news and
Nymox Pivotal Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint. Company Plans to File For Regulatory Approvals For Fexapotide Triflutate (NX-1207).
July 27, 2015:
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that the Companys U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo.
July 16, 2015:
July 16, 2015: On July 15, 2015, the Board of Directors of Nymox Pharmaceutical Corporation (NASDAQ: NYMX) approved the engagement of Cutler & Co., LLC to serve as the Company’s new independent registered public accounting firm to replace KPMGLLP.
July 13, 2015:
Nymox Pharmaceutical Corporation is pleased to announce the appointment of Erik Danielsen as Chief Financial Officer of the Company.
June 16, 2015:
Nymox Pharmaceutical Corporation is pleased to announce that it has recently completed financing for a total of $850,000 at prices of $1.25-$1.66.
May 15, 2015:
Nymox Pharmaceutical Corporation announced today its financial results for the first quarter of 2015 prepared in accordance with International Financial Reporting Standards.
April 20, 2015:
Nymox Pharmaceutical Corporation announced today long-term clinical trial results from the Companys NX-1207 prostate cancer study NX03-0040.